The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins
Dyslipidemia is known to be significantly associated with an increased risk of CAD and lipid-lowering strategy is the key approach for primary and secondary prevention.
In this cohort study, D. Kanda et al. (Kagoshima University, Japan) aimed to examine the clinical meaning of LDL-C ＜70 mg/dL and non-HDL-C ＜100 mg/dL on the occurrence of new lesions among Japanese patients with stable angina who were prescribed with strong statins.
Take-home message: This study shows that non-HDL-C ≥ 100 mg/dL, but not LDL-C ≥70 mg/dL, is an independent risk factor for the occurrence of new lesions 9 months and ≤ 2 years after PCI among stable angina patients with strong statins. Residual risk after PCI should be considered by assessing not only DM but also non-HDL-C beyond the scope of LDL-C- lowering therapy with strong statins.